Literature DB >> 17328868

Antagonistic targeting of the histamine H3 receptor decreases caloric intake in higher mammalian species.

Kjell Malmlöf1, Sven Hastrup, Birgitte Schellerup Wulff, Barbara C Hansen, Bernd Peschke, Claus Bekker Jeppesen, Rolf Hohlweg, Karin Rimvall.   

Abstract

The main purpose of this study was to examine the effects of a selective histamine H(3) receptor antagonist, NNC 38-1202, on caloric intake in pigs and in rhesus monkeys. The compound was given intragastrically (5 or 15 mg/kg), to normal pigs (n=7) and subcutaneously (1 or 0.1mg/kg) to obese rhesus monkeys (n=9). The energy intake recorded following administration of vehicle to the same animals served as control for the effect of the compound. In addition, rhesus monkey and pig histamine H(3) receptors were cloned from hypothalamic tissues and expressed in mammalian cell lines. The in vitro antagonist potencies of NNC 38-1202 at the H(3) receptors were determined using a functional GTPgammaS binding assay. Porcine and human H(3) receptors were found to have 93.3% identity at the amino acid level and the close homology between the monkey and human H(3) receptors (98.4% identity) was confirmed. The antagonist potencies of NNC 38-1202 at the porcine, monkey and human histamine H(3) receptors were high as evidenced by K(i)-values being clearly below 20 nM, whereas the K(i)-value on the rat H(3) receptor was significantly higher (56+/-6.0 nM). NNC 38-1202, given to pigs in a dose of 15 mg/kg, produced a significant (p<0.05) reduction (55%) of calorie intake compared with vehicle alone, (132.6+/-10.0 kcal/kgday versus 59.7+/-10.2 kcal/kgday). In rhesus monkeys administration of 0.1 and 1mg/kg decreased (p<0.05) average calorie intakes by 40 and 75%, respectively. In conclusion, the present study demonstrates that antagonistic targeting of the histamine H(3) receptor decreases caloric intake in higher mammalian species.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17328868     DOI: 10.1016/j.bcp.2007.01.034

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Evidence for the role of histamine H3 receptor in alcohol consumption and alcohol reward in mice.

Authors:  Saara Nuutinen; Minnamaija Lintunen; Jenni Vanhanen; Tiia Ojala; Stanislav Rozov; Pertti Panula
Journal:  Neuropsychopharmacology       Date:  2011-06-08       Impact factor: 7.853

2.  Discovery of a potent thiadiazole class of histamine h3 receptor antagonist for the treatment of diabetes.

Authors:  Ashwin U Rao; Ning Shao; Robert G Aslanian; Tin-Yau Chan; Sylvia J Degrado; Li Wang; Brian McKittrick; Mary Senior; Robert E West; Shirley M Williams; Ren-Long Wu; Joyce Hwa; Bhuneshwari Patel; Shuqin Zheng; Christopher Sondey; Anandan Palani
Journal:  ACS Med Chem Lett       Date:  2011-11-21       Impact factor: 4.345

3.  Proxyfan acts as a neutral antagonist of histamine H3 receptors in the feeding-related hypothalamic ventromedial nucleus.

Authors:  R H Clapp; S M Luckman
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 4.  Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.

Authors:  Philippe Devillier; Nicolas Roche; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Comparison of Different 2D and 3D-QSAR Methods on Activity Prediction of Histamine H3 Receptor Antagonists.

Authors:  Siavoush Dastmalchi; Maryam Hamzeh-Mivehroud; Karim Asadpour-Zeynali
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.